- Home
- CMMB vs MNDO Comparison
CMMB vs MNDO Comparison
Compare CMMB & MNDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- MNDO
- Stock Information
- Founded
- CMMB 2004
- MNDO 1995
- Country
- CMMB Israel
- MNDO Israel
- Employees
- CMMB N/A
- MNDO N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- MNDO EDP Services
- Sector
- CMMB Health Care
- MNDO Technology
- Exchange
- CMMB Nasdaq
- MNDO Nasdaq
- Market Cap
- CMMB 22.0M
- MNDO 24.2M
- IPO Year
- CMMB N/A
- MNDO 2000
- Fundamental
- Price
- CMMB $3.02
- MNDO $1.19
- Analyst Decision
- CMMB Strong Buy
- MNDO
- Analyst Count
- CMMB 2
- MNDO 0
- Target Price
- CMMB $26.50
- MNDO N/A
- AVG Volume (30 Days)
- CMMB 108.4K
- MNDO 58.0K
- Earning Date
- CMMB 08-14-2025
- MNDO 08-11-2025
- Dividend Yield
- CMMB N/A
- MNDO 18.41%
- EPS Growth
- CMMB N/A
- MNDO N/A
- EPS
- CMMB N/A
- MNDO 0.15
- Revenue
- CMMB N/A
- MNDO $20,155,000.00
- Revenue This Year
- CMMB N/A
- MNDO N/A
- Revenue Next Year
- CMMB N/A
- MNDO N/A
- P/E Ratio
- CMMB N/A
- MNDO $8.00
- Revenue Growth
- CMMB N/A
- MNDO N/A
- 52 Week Low
- CMMB $3.02
- MNDO $1.02
- 52 Week High
- CMMB $10.20
- MNDO $2.13
- Technical
- Relative Strength Index (RSI)
- CMMB 19.63
- MNDO 41.52
- Support Level
- CMMB $3.32
- MNDO $1.10
- Resistance Level
- CMMB $3.86
- MNDO $1.20
- Average True Range (ATR)
- CMMB 0.28
- MNDO 0.05
- MACD
- CMMB -0.03
- MNDO 0.01
- Stochastic Oscillator
- CMMB 2.65
- MNDO 63.04
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About MNDO MIND C.T.I. Ltd.
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.